SHANGHAI, June 30, 2026 /PRNewswire/ -- Tsingke Biotech recently hosted the Oligonucleotide Drug Salon at the Hilton Shanghai Zhangjiang, bringing together experts from academia, biopharmaceutical companies, investment firms, and industry service organizations to discuss technological innovation, CMC development, delivery technologies, regulatory strategies, and commercialization pathways in the rapidly evolving field of oligonucleotide therapeutics.

As momentum in the global nucleic acid medicine sector continues to build, advances in chemistry, delivery systems, manufacturing, and clinical research are broadening the therapeutic applications of these modalities. The event provided a platform for stakeholders across the value chain to exchange perspectives on emerging trends and explore opportunities for collaboration and industry growth.

Advancing Industry Collaboration

Opening the event, Shijin Ma, CEO of Tsingke Biotech, noted that China's small nucleic acid industry is entering a new stage of development, evolving from technology adoption toward innovation-driven growth.

"Open collaboration has become increasingly important as the industry advances," said Ma. "Progress in nucleic acid therapeutics depends on coordinated innovation across the value chain—from nucleic acid synthesis and delivery technologies to CMC development and regulatory advancement. Through this forum, we hope to encourage meaningful dialogue and strengthen connections across the industry."

Expert Perspectives on Technology, Development, and Regulation

The scientific program featured presentations covering key aspects of small nucleic acid drug development.

Dr. Jun Bai, Head of the Nucleic Acid Research Department at Haichang Biotech, reviewed the evolution of siRNA therapeutics from sequence design and chemical modification to delivery platform development. He highlighted recent advances in GalNAc conjugates, antibody-oligonucleotide conjugates (AOCs), dual-targeting strategies, adipose tissue targeting, and kidney-directed delivery approaches.

Professor Qixian Chen, Chief Scientist of Tsingke Biotech and Professor at the Yangtze River Delta Intelligent Green Innovation Center of Zhejiang University, shared research progress in nucleic acid delivery technologies. His presentation focused on approaches designed to overcome intracellular delivery barriers and improve delivery beyond the liver, including applications in central nervous system and tumor-targeted therapies.

Providing a regulatory perspective, Dr. Yaning Wang, Founder and CEO of Shanghai Ruiningkang Bio, former Director of the Clinical Quantitative Pharmacology Review Division at the U.S. Food and Drug Administration (FDA), and Chief Scientific Advisor to Tsingke Biotech, analyzed representative FDA approval cases and discussed scientific evidence generation, surrogate endpoint selection, and key considerations in regulatory decision-making for nucleic acid therapeutics.

Dr. Chengjiang Zhao, Co-founder of Youjia (Hangzhou) Biomedical Technology, examined critical CMC considerations from candidate selection through IND submission. Drawing on project experience, he highlighted the importance of strategic planning across process development, analytical methods, formulation development, quality studies, and toxicology batch manufacturing.

Representing the host organization, Dr. Xichao Chen, Head of Small Nucleic Acid Technology at Tsingke Biotech, introduced the company's integrated oligonucleotide drug development platform, outlining capabilities spanning sequence design, modification optimization, process development, and CMC studies.

Industry Leaders Discuss the Road Ahead

The event concluded with a roundtable discussion that brought together perspectives from across scientific innovation, CMC development, regulatory review, capital markets, and industry collaboration.

Participants agreed that as the sector continues to mature, long-term competitiveness will depend not only on individual technological breakthroughs, but also on the ability to integrate scientific innovation, manufacturing capabilities, regulatory expertise, and broader ecosystem resources.

Supporting the Full Lifecycle of Small Nucleic Acid Drug Development

As one of the early participants in China's nucleic acid industry, Tsingke Biotech has focused on building foundational technologies and industrial capabilities to advance nucleic acid-based therapeutics.

Leveraging proprietary nucleic acid synthesis equipment, core raw material technologies, and integrated manufacturing platforms, the company provides services spanning both research-grade and GMP-grade production. These capabilities support programs from early discovery through process development and commercialization.

Tsingke Biotech's service portfolio includes:

• Nucleic Acid Synthesis and Modification Platform: Customized development of siRNA, ASO, and other modified oligonucleotides, including 2'-OMe, 2'-F, phosphorothioate (PS), and GalNAc conjugation technologies.
• Small Nucleic Acid Drug CDMO Platform: Services covering hit screening, lead optimization, process development, analytical testing, and IND-enabling studies.
• Analytical Testing Platform: Quality research and analytical support for both development and regulatory submission.

The company is also exploring the application of artificial intelligence in nucleic acid drug development, including sequence design, candidate screening, and process optimization, with the goal of improving efficiency and accelerating development timelines.

Looking Ahead

The global field of small nucleic acid therapeutics continues to expand, driven by progress in basic research, clinical development, and manufacturing technologies that are enabling wider adoption of this modality. Tsingke Biotech remains committed to collaborating with academic institutions, innovative biopharmaceutical companies, and industry partners to advance technological innovation and accelerate the development of new therapies for patients worldwide.

About Tsingke Biotech

Tsingke Biotech is a leading innovator in synthetic biology, with a mission to build "the world's great gene factory." Combining proprietary reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing technologies, Tsingke Biotech provides efficient and high-quality gene synthesis services. Its work supports industries ranging from biopharma to agriculture, food, and environmental sciences.

For news and updates, follow Tsingke Biotech on LinkedIn.

Media contact: 

Mandy Qiu

qiumanqi@tsingke.com.cn 

+86-13470470511

View original content:https://www.prnewswire.co.uk/news-releases/tsingke-biotech-hosts-shanghai-salon-on-oligonucleotide-drugs-spotlighting-next-gen-rna-therapeutics-302811515.html

Die Einigung zwischen den USA und dem Iran auf ein Rahmenabkommen zur Beendigung des Iran-Kriegs sorgt in der Handelsschifffahrt für vorsichtige Erleichterung. Besonders im Fokus steht die Straße von Hormus, eine der wichtigsten Seepassagen für den weltweiten Öl- und Flüssiggas-Handel. Seit Beginn des Konflikts Ende Februar ist die Meerenge weitgehend blockiert, zahlreiche Handelsschiffe sitzen im Persischen Golf fest. Nun soll die Passage nach der geplanten Unterzeichnung des Abkommens wieder geöffnet werden.

US-Präsident Donald Trump kündigte an, dass die Straße von Hormus nach dem Abschluss der Vereinbarung wieder für den Verkehr freigegeben werden solle. Die Unterzeichnung ist für Freitag in Genf vorgesehen. Für die deutsche Handelsschifffahrt wäre dies ein entscheidender Schritt zur Normalisierung. „Die Signale aus den Gesprächen zwischen den USA und dem Iran machen auch der Schifffahrt Hoffnung“, sagte Martin Kröger, Hauptgeschäftsführer des Verbands Deutscher Reeder (VDR). Zugleich mahnte er, es müsse sich erst zeigen, ob die Passage dauerhaft sicher befahrbar sein werde. Man sei „vorsichtig optimistisch“.

Die Branche hat allen Grund, auf rasche Entspannung zu hoffen. Nach Angaben des VDR sitzen aktuell noch 46 Schiffe deutscher Reedereien mit rund 1.000 Seeleuten im Persischen Golf fest. Die Blockade der Meerenge trifft nicht nur die Reedereien, sondern bremst den globalen Energiehandel. Die UN-Sonderorganisation für Seeschifffahrt (IMO) begrüßte die Einigung ausdrücklich. Seit Ausbruch des Konflikts wurden der IMO zufolge 46 Angriffe auf Handelsschiffe in der Region bestätigt, bei denen 14 Seeleute ums Leben kamen.

Trotz der diplomatischen Fortschritte sehen Branchenverbände die Lage in der Region weiter kritisch. Der internationale Schifffahrtsverband Bimco bewertet die Sicherheitslage in der Straße von Hormus auch nach Bekanntwerden des Rahmenabkommens als instabil. Eine Durchfahrt bleibe sehr riskant, heißt es aus dem Verband. Für Reeder und Charterer stellt sich damit die Frage, wie schnell und in welchem Umfang sie ihre Routen wieder über die Meerenge führen können – oder ob Ausweichrouten zumindest mittelfristig bestehen bleiben müssen.

Für den Moment überwiegt in der Schifffahrt die Hoffnung, dass die geplante Vereinbarung in Genf die Voraussetzungen für eine nachhaltige Entspannung an einem der neuralgischsten Punkte des globalen Seehandels schafft. Ob und wie schnell sich die Zahl der festliegenden Schiffe reduziert und sich die Risikoeinschätzungen der Versicherer und Verbände anpassen, dürfte entscheidend dafür sein, wann sich der Verkehr durch die Straße von Hormus wieder weitgehend normalisiert.